Published in Mol Pharmacol on July 01, 1987
Binding properties of nine 4-diphenyl-acetoxy-N-methyl-piperidine (4-DAMP) analogues to M1, M2, M3 and putative M4 muscarinic receptor subtypes. Br J Pharmacol (1992) 1.14
Functional and binding studies with muscarinic M2-subtype selective antagonists. Br J Pharmacol (1989) 0.94
Binding and functional properties of antimuscarinics of the hexocyclium/sila-hexocyclium and hexahydro-diphenidol/hexahydro-sila-diphenidol type to muscarinic receptor subtypes. Br J Pharmacol (1989) 0.87
Binding and functional properties of hexocyclium and sila-hexocyclium derivatives to muscarinic receptor subtypes. Br J Pharmacol (1994) 0.81
Investigating the interaction of McN-A-343 with the M2 muscarinic receptor using its nitrogen mustard derivative. Biochem Pharmacol (2009) 0.80
Antimuscarinic action of liriodenine, isolated from Fissistigma glaucescens, in canine tracheal smooth muscle. Br J Pharmacol (1994) 0.76
International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev (1998) 2.30
Sebaceous carcinoma. J Am Acad Dermatol (1995) 1.75
Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas. Med Pediatr Oncol (2000) 1.66
Secretion of hydrolases by perfused fragments of rat pancreas: effect of calcium. Am J Physiol (1971) 1.62
Basaloid follicular hamartoma: a histologic diagnosis with diverse clinical presentations. Arch Dermatol (1993) 1.52
Does a radiolabelled ligand bind to a homogeneous population of non-interacting receptor sites? Trends Pharmacol Sci (1995) 1.50
Localization of transforming growth factor beta 1 and its latent binding protein in human chronic pancreatitis. Gastroenterology (1995) 1.44
Interleukin 10 prevents necrosis in murine experimental acute pancreatitis. Gastroenterology (1995) 1.37
The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol (1995) 1.35
Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res (2000) 1.29
Binding of selective antagonists to four muscarinic receptors (M1 to M4) in rat forebrain. Mol Pharmacol (1990) 1.28
Transforming growth factor beta promotes development of fibrosis after repeated courses of acute pancreatitis in mice. Gastroenterology (1996) 1.26
In vitro action of bombesin and bombesin-like peptides on amylase secretion, calcium efflux, and adenylate cyclase activity in the rat pancreas: a comparison with other secretagogues. J Clin Invest (1976) 1.25
Telephone and in-person proxy agreement between stroke patients and caregivers for the functional independence measure. Am J Phys Med Rehabil (1996) 1.23
The stimulus-secretion coupling of glucose-induced insulin release. XLVI. Physiological role of L-glutamine as a fuel for pancreatic islets. Mol Cell Endocrinol (1980) 1.19
Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A (1994) 1.16
Multisystemic production of interleukin 10 limits the severity of acute pancreatitis in mice. Gut (1998) 1.16
In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides (1997) 1.15
Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction. J Biol Chem (2001) 1.14
Binding properties of nine 4-diphenyl-acetoxy-N-methyl-piperidine (4-DAMP) analogues to M1, M2, M3 and putative M4 muscarinic receptor subtypes. Br J Pharmacol (1992) 1.14
In vitro interactions of gastrointestinal hormones on cyclic adenosine 3':5'-monophosphate levels and amylase output in the rat pancreas. Gastroenterology (1975) 1.12
Rat cardiac muscarinic receptors. I. Effects of guanine nucleotides on high- and low-affinity binding sites. Mol Pharmacol (1982) 1.09
Demonstration of biological activity of brain gastrin-like peptidic material in the human: its relationship with the COOH-terminal octapeptide of cholecystokinin. Proc Natl Acad Sci U S A (1978) 1.08
Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor. Peptides (2000) 1.08
Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumours. Gut (1995) 1.07
Pancreatic secretion of total protein and of three hydrolases collected in healthy subjects via duodenoscopic cannulation. Effects of secretin, pancreozymin, and caerulein. Gastroenterology (1975) 1.05
Development of high affinity selective VIP1 receptor agonists. Peptides (1997) 1.04
The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors. Peptides (1996) 1.04
Contribution of the second transmembrane helix of the secretin receptor to the positioning of secretin. FEBS Lett (1998) 1.04
Activation of p38 and p42/44 MAP kinase in neuropathic pain: involvement of VPAC2 and NK2 receptors and mediation by spinal glia. Mol Cell Neurosci (2005) 1.03
Exocrine pancreas: evidence for topographic partition of secretory function. Science (1975) 1.03
Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. Endocrinology (1985) 1.03
Rat pancreatic hydrolases from birth to weaning and dietary adaptation after weaning. Am J Physiol (1971) 1.02
Affinity profiles of hexahydro-sila-difenidol analogues at muscarinic receptor subtypes. Eur J Pharmacol (1989) 1.01
The stimulus-secretion coupling of amino acid-induced insulin release. Metabolic interaction of L-glutamine and 2-ketoisocaproate in pancreatic islets. Biochim Biophys Acta (1981) 1.00
Role of charged amino acids conserved in the vasoactive intestinal polypeptide/secretin family of receptors on the secretin receptor functionality. Peptides (1999) 0.99
Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes. Endocrinology (1985) 0.99
Effect of a high-fat diet on obese-hyperglycaemic and non-obese Bar Harbor mice. Diabetologia (1971) 0.98
Factors regulating biosynthesis, intracellular transport and secretion of amylase and lipase in the rat exocrine pancreas. Horm Metab Res (1971) 0.98
Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem Biophys Res Commun (1994) 0.97
The human heart beta-adrenergic receptors. II. Coupling of beta 2-adrenergic receptors with the adenylate cyclase system. Mol Pharmacol (1983) 0.97
Thermodynamics of the interaction of insulin with its receptor. J Biol Chem (1979) 0.97
Purification of a novel pancreatic secretory factor (PSF) and a novel peptide with VIP- and secretin-like properties (helodermin) from Gila monster venom. FEBS Lett (1984) 0.95
The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass. Peptides (1997) 0.95
Heart receptors for VIP, PHI and secretin are able to activate adenylate cyclase and to mediate inotropic and chronotropic effects. Species variations and physiopathology. Peptides (1984) 0.95
Effects of somatostatin on pancreatic exocrine function. Interaction with secretin. Biochem Biophys Res Commun (1975) 0.94
Kinetic studies of [3H]-N-methylscopolamine binding to muscarinic receptors in the rat central nervous system: evidence for the existence of three classes of binding sites. Mol Pharmacol (1986) 0.94
Presence of highly selective receptors for PACAP (pituitary adenylate cyclase activating peptide) in membranes from the rat pancreatic acinar cell line AR 4-2J. FEBS Lett (1990) 0.94
In vivo effects of pancreozymin, secretin, vasoactive intestinal polypeptide and pilocarpine on the levels of cyclic AMP and cyclic GMP in the rat pancreas. FEBS Lett (1974) 0.93
A calcium-dependent protein activator of guanosine 3':5'-monophosphate phosphodiesterase in bovine and rat pancreas. Isolation, properties and levels in vivo. Eur J Biochem (1977) 0.93
Mutations of aromatic residues in the first transmembrane helix impair signalling by the secretin receptor. Receptors Channels (1999) 0.93
Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands. Mol Pharmacol (1999) 0.93
Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors. Eur J Pharmacol (1998) 0.93
Helodermin has a VIP-like effect upon canine blood flow. Peptides (1986) 0.93
Binding in vitro of vasoactive intestinal peptide on isolated acini of rat parotid glands. Arch Oral Biol (1985) 0.93
Scorpion venom inhibits carbamylcholine-induced 86rubidium efflux from rat parotid acini. FEBS Lett (1987) 0.93
RDC1 may not be VIP receptor. Trends Pharmacol Sci (1992) 0.92
Molecular mechanisms involved in vasoactive intestinal peptide receptor activation and regulation: current knowledge, similarities to and differences from the A family of G-protein-coupled receptors. Biochem Soc Trans (2007) 0.92
Primary structure of helodermin, a VIP-secretin-like peptide isolated from Gila monster venom. FEBS Lett (1984) 0.92